Atria Investments Inc Sells 315 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

Atria Investments Inc decreased its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 15.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,700 shares of the financial services provider’s stock after selling 315 shares during the quarter. Atria Investments Inc’s holdings in iShares Biotechnology ETF were worth $248,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the stock. Highline Wealth Partners LLC purchased a new position in iShares Biotechnology ETF in the 3rd quarter worth approximately $30,000. Bbjs Financial Advisors LLC purchased a new position in shares of iShares Biotechnology ETF in the second quarter worth $31,000. Voisard Asset Management Group Inc. bought a new position in shares of iShares Biotechnology ETF during the third quarter valued at $59,000. Chris Bulman Inc purchased a new stake in shares of iShares Biotechnology ETF during the second quarter valued at $64,000. Finally, Eastern Bank bought a new stake in iShares Biotechnology ETF in the 3rd quarter worth about $65,000. 62.45% of the stock is owned by institutional investors.

iShares Biotechnology ETF Stock Performance

IBB opened at $137.96 on Friday. The company’s 50-day simple moving average is $143.43 and its two-hundred day simple moving average is $141.81. iShares Biotechnology ETF has a 52-week low of $117.28 and a 52-week high of $150.57.

iShares Biotechnology ETF Dividend Announcement

The business also recently disclosed a dividend, which was paid on Monday, September 30th. Investors of record on Wednesday, September 25th were given a dividend of $0.2005 per share. The ex-dividend date of this dividend was Wednesday, September 25th.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.